Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe page now presents an error page indicating the content is unavailable, including the HTML skeleton and header/footer, which removes the study information and linked documents from view.SummaryDifference16%

- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4, indicating a minor system update; no study details or visible content were altered.SummaryDifference0.1%

- Check56 days agoChange DetectedRevision updated from v3.6.2 to v3.6.3, indicating a new site build. This change appears to be a minor platform update and does not reflect changes to the study content on this page.SummaryDifference0.1%

- Check63 days agoChange DetectedThe site software revision was updated from v3.6.0 to v3.6.2, indicating a minor release. No changes to the study details or visible page content are introduced.SummaryDifference0.1%

- Check78 days agoChange DetectedThe page now indicates that recruitment is closed and adds new help/navigation sections. The Intervention/Treatment label is updated, and the revision footer shows v3.6.0 compared to v3.5.5.SummaryDifference0.5%

- Check85 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, indicating a new platform release. The change does not alter the study details or visible content on the page.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.